China Discount Price Amlodipine And Hydrochlorothiazide Tablets - Rimegepant – CPF manufacturers and suppliers

Discount Price Amlodipine And Hydrochlorothiazide Tablets - Rimegepant – CPF

Short Description:

Product Detail

Product Tags

Feedback (2)

To become the stage of realizing dreams of our employees! To build a happier, much more united and far more professional team! To reach a mutual profit of our clients, suppliers, the society and ourselves for Celecoxib Manufacturer, Baloxavir Marboxil For Uncomplicated Influenza, Bictegravir Manufacturer, If possible, please send your requirements with a detailed list including the style/item and quantity you require. We will then send our best prices to you.

Discount Price Amlodipine And Hydrochlorothiazide Tablets - Rimegepant – CPF Detail:

Rimegepant is a small molecule inhibitor of the calcitonin gene-related peptide (CGRP) receptor that blocks the action of CGRP, a potent vasodilator believed to play a role in migraine headaches. Rimegepant is approved for treatment of acute migraine attacks. In clinical trials, rimegepant was generally well tolerated with only rare instances of transient serum aminotransferase elevations during therapy and with no reported instances of clinically apparent liver injury.

Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] are the only members of the “gepants” family of medications remaining in development, and the only CGRP antagonists that possess oral bioavailability. The current standard of migraine therapy involves abortive treatment with “triptans”, such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due to their vasoconstrictive properties. Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore safer for use in patients with contraindications to standard therapy.

Rimegepant is a Calcitonin Gene-related Peptide Receptor Antagonist. The mechanism of action of rimegepant is as a Calcitonin Gene-related Peptide Receptor Antagonist.

2018 GMP-2
原料药GMP证书201811（captopril ,thalidomide etc）
GMP-of-PMDA-in-Chanyoo-平成28年08月03日　Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect.

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.

VIEW MORE

VIEW MORE

International cooperation

Domestic cooperation

Product detail pictures:

Related Product Guide:

"Sincerity, Innovation, Rigorousness, and Efficiency" may be the persistent conception of our organization for that long-term to establish jointly with customers for mutual reciprocity and mutual gain for Discount Price Amlodipine And Hydrochlorothiazide Tablets - Rimegepant – CPF , The product will supply to all over the world, such as: Southampton, Chile, Georgia, Satisfaction and good credit to every customer is our priority. We focus on every detail of order processing for customers till they have received safe and sound products with good logistics service and economical cost. Depending on this, our products are sold very well in the countries in Africa, the Mid-East and Southeast Asia.

Agomelatine